Helus Pharma announced that Michael Cola has stepped down as Chief Executive Officer effective immediately at the request of the Board. Co-founder and Executive Chairman Eric So has been appointed as Interim CEO while the company conducts a search for a permanent successor.
The leadership transition is intended to ensure continuity as Helus Pharma advances its clinical pipeline, including the anticipated fourth-quarter topline data readout from the APPROACH trial of HLP003, while maintaining focus on long-term value creation for patients and shareholders. HLP003, a proprietary novel serotonergic agonist currently in Phase 3 development, has received FDA Breakthrough Therapy designation for adjunctive treatment of major depressive disorder.
Helus Pharma, the commercial operating name of Cybin Inc. (founded in 2019), is a clinical-stage pharmaceutical company developing proprietary novel serotonergic agonists designed to activate serotonin pathways believed to promote neuroplasticity. Beyond HLP003, the company is also developing HLP004, a proprietary novel serotonergic agonist in Phase 2 for generalized anxiety disorder, and maintains an extensive research portfolio of investigational novel serotonergic agonists.
The company operates in Canada, the United States, the United Kingdom, and Ireland.
This article is an AI-assisted summary. All facts and figures are drawn from the original report: https://www.financialcontent.com/article/nnwire-2026-4-20-investornewsbreaks-helus-pharmatm-nasdaq-help-cboe-ca-help-ceo-steps-down-eric-so-named-interim-chief-executive-office